Advertisement

Topics

Latest "Cambridge Innovation Center" News Stories

00:57 EST 19th January 2019 | BioPortfolio

Here are the most relevant search results for "Cambridge Innovation Center" found in our extensive news archives from over 250 global news sources.

More Information about Cambridge Innovation Center on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Cambridge Innovation Center for you to read. Along with our medical data and news we also list Cambridge Innovation Center Clinical Trials, which are updated daily. BioPortfolio also has a large database of Cambridge Innovation Center Companies for you to search.

Showing "Cambridge Innovation Center" News Articles 1–25 of 9,400+

Friday 18th January 2019

U.S.-based Shearwater Health and Philippines-based Asian Hospital and Medical Center Create Transpacific Partnership to Solve Global Nursing Shortage

METRO MANILA, Philippines, Jan. 18, 2019 /PRNewswire/ -- Hospitals and other healthcare providers inside the United States are challenged daily to adequately staff nurses amidst an ongoing shortage with no end in sight. Shearwater Health contributes to increasing the supply of nurses by bringing international nurses to the U.S., which helps providers sustain excellent patient care.


In THREE DAYS the application process for #statmadness closes! If you think your institution is the MVP of biomedical innovation then there's no more time to wait. Enter today: https://buff.ly/2CxeD7d pic.twitter.com/DrUkbWruAy

In THREE DAYS the application process for #statmadness closes! If you think your institution is the MVP of biomedical innovation then there's no more time to wait. Enter today: https://buff.ly/2CxeD7d  pic.twitter.com/DrUkbWruAy

Mass Innovation Labs is Now SmartLabs

Premier Biotech Lab Space Announces New Name CAMBRIDGE, Mass. (PRWEB) January 18, 2019 Boston-based Laboratory as a Service (LaaS) leader, Mass Innovation Labs, has changed its name to SmartLabs in an effort to better express its continued expansion and service offerings for biotech and life sciences companies. “Meeting the challenges of innovation calls for a new kind of lab: one that is mor...


We don’t have to choose between innovation & affordability. Last year, in the midst of @US_FDA approving a record 59 new treatments, medicines prices grew just 1.6% according to @Altarum. More from @Hlcampbe: https://catalyst.phrma.org/two-new-reports-

We don’t have to choose between innovation & affordability. Last year, in the midst of @US_FDA approving a record 59 new treatments, medicines prices grew just 1.6% according to @Altarum. More from @Hlcampbe: https://catalyst.phrma.org/two-new-reports-show-medicines-price-growth-continues-to-decline ….

New government data show medicine price growth continues to decline

Last year, the U.S. Food and Drug Administration approved a record 59 new treatments and cures. During this incredible period of innovation, medicine price growth continued to slow dramatically.

MEDIA ADVISORY: Fabric Genomics™ Senior Scientist to Discuss Role of Genomics and Artificial Intelligence in Advancing Precision Medicine – Tuesday, January 22nd

Precision Medicine World Conference - Fabric Genomics:       WHAT: Presentation, How Geno...

How a Georgia health system found success using structured brain tumor reporting

After implementing a structured reporting template for brain tumor imaging, radiologists became more confident in their reports and felt they better facilitated decision-making, according to a single-center study published in Academic Radiology. Patients were also more satisfied with their reports.

What’s So ‘Indecent’ About Female Pleasure?

A consumer technology innovation award was revoked from a company that makes a hands-free sex toy. The reason, some believe, is that the product is made for women.

Shady Grove Fertility’s Expansion in 2018 Makes Accessing Highly Specialized Fertility Care More Convenient and Paying for Care More Affordable

Known for its scientific leadership, continuous world-class innovation, and personalized care, Shady Grove Fertility, with 33 locations, has made improving access to infertility care a priority by expanding their services and adding new locations and physicians in 2018. ROCKVILLE, Md. (PRWEB) January 18, 2019 Shady Grove Fertility (SGF), a pioneer in reproductive medicine, placed a strong emphasi...

Key Questions Before Partnering With Telehealth Specialty Providers

David Raths, Contributing EditorThe California Telehealth Resource Center (CTRC) has come up with 20 questions clinics should ask specialty telehealth providers when vetting different offerings

Dr. John Mendelsohn, 82, Researcher Who Led Top Cancer Center, Dies

After pioneering a targeted cancer therapy, he oversaw MD Anderson in Houston as it gained a reputation as the nation’s top cancer hospital.

Success At Cleveland Clinic And The Future Of Healthcare

Health care is unique in that it impacts every person and is a major cost and health component for every CEO. In this article I interview the CEO of Cleveland Clinic a top medical center globally.

CMS introduces new models to lower drug prices in Part D, Medicare Advantage

CMS’ Center for Medicare and Medicaid Innovation (CMMI) has announced a new model that aims to lower prescription drug prices in Medicare Part D and introduced several updates to Medicare Advantage (MA) plans.

Outdoorsy’s Big Haul & Other Startup Fundraising in TX Tech News

Let’s catch up with the latest innovation news in Texas. —TeVido, an Austin biotech, has raised $1.2 million to help fund a new facility in which the company can use a patient’s own cells to create personalized pigment cell grafts to treat vitiligo, a loss of skin color that affects about 1 percent of the […]

The Assistance Fund Announces New Financial Assistance Program for Individuals with Paroxysmal Nocturnal Hemoglobinuria

The Assistance Fund, an independent charitable patient assistance foundation that helps patients and families facing high out-of-pocket medical costs, today announced the launch of a new financial assistance program for individuals living with Paroxysmal Nocturnal Hemoglobinuria (PNH). PNH is a rare acquired blood disease that leads to premature d...

Obsidian Therapeutics and Celgene Collaborate to Develop Novel Cell Therapies that Utilize Obsidian’s Destabilizing Domain Technology

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Obsidian Therapeutics, a biotechnology company developing cell therapies with pharmacologic operating systems, today announced a strategic collaboration with Celgene Corporation (NASDAQ: CELG) for the discovery and development of novel, regulated cell therapies that utilize Obsidian’s Destabilizing Domain (DD) technology. Specifically, the collab...

Advanced Studies and Latest Innovation Helping Hemp/CBD Companies Increase Yields

NewsThe hottest commodity today is growing hemp for CBD extraction. Contributed Author: 

Which Came First: Cannabis Use Or Psychotic Disorders? Scientists Weigh In On Dangers, Myths

Top scientists who specialize in marijuana research are divided over whether the drug can lead to disorders like schizophrenia. “I’ve been doing this research for 25 years, and it’s polarizing even among academics,” said Margaret Haney, a professor of neurobiology at Columbia University Medical Center. Other public health news focuses on climate change's dangers; pain's origins in the brai...

We too believe that #IPrights are critical to foster #innovation & provide incentives for future R&D investment. Read more from @ThomasCueni of @IFPMA: https://twitter.com/IFPMA/status/1085816394615185408 …

We too believe that #IPrights are critical to foster #innovation & provide incentives for future R&D investment. Read more from @ThomasCueni of @IFPMA: https://twitter.com/IFPMA/status/1085816394615185408 …

Dr. John Mendlein to Transition to an Advisory Role at Moderna and Join Flagship Pioneering as an Executive Partner

Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that John Mendlein, Ph.D., President of Corporate and Product Strategy, will be leaving the Company effective February 1, 2019 to join Flagship Pi...

Europe Looks to Cells for a Healthier Future

NewsAn initiative led by European researchers will have one year to develop a plan to embed its vision for a healthier future within the research and innovation landscape.

Obsidian Therapeutics Announces Strategic Collaboration with Celgene to Develop Novel Cell Therapies with Tunable Immunomodulatory Factors, Opening Potential for CAR-T and Other Cellular Medicines in New Settings

Companies enter into multi-year strategic collaboration with Celgene receiving exclusive options to license cell therapies that utilize Obsidian’s Destabilizing Domain technology to modulate IL12 and CD40L activity Collaboration represents Obsidian’s first major partnership and further expands Celgene’s capabilities in cellular immunotherapy...

Overlake Medical Center and EvergreenHealth Participating in Trial to Enhance Mothers’ Childbirth Experience and Safety

Quality improvement program aims to reduce C-sections and increase adherence to birth plans EvergreenHealth and Overlake Medical Center announced today that they are collaborating as two of only four hospitals in the country partnering with Ariadne Labs—a joint center of Brigham and Women’s Hospital and the Harvard T.H. Chan School of Public Health...

Teleflex to Showcase the MANTA™ Vascular Closure Device from the Recently Acquired Essential Medical, Inc. at the Annual Meeting of the Leipzig Interventional Course (LINC) 2019, in Leipzig, Germany, on January 22-25

Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies with solutions in the fields of vascular and interventional access, surgical and cardiac care, will showcase the MANTA™ Vascular Closure Device as well as its portfolio for peripheral interventions at the Annual Meeting of the Leipzig Interventional Course (LINC) 2019, in ...

Autifony Therapeutics achieves first milestone in agreement with Boehringer Ingelheim for a novel therapeutic approach to a range of CNS disorders

Stevenage, UK – 18 January 2019 – Autifony Therapeutics Limited (“Autifony”), a clinical stage company developing new drugs to treat serious disorders of the nervous system, today announced that the first milestone has successfully been achieved under Autifony’s option agreement with Boehringer Ingelheim. As announced previously, Boehringer Ingelheim acquired an exc...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks